Pembrolizumab vs Chemo Improves PFS in Endometrial Cancer

1 source1 article First seen 3 days ago Updated 3 days ago United States Truth score 38

Save Like Comments Compare coverage

Summary

Compared with chemotherapy, pembrolizumab monotherapy is associated with improved quality of life and reduces severe treatment-related adverse events.

Description from Medscape.

Who is covering this

Medscape Center Factuality: Mostly factual US 3 days ago
Pembrolizumab vs Chemo Improves PFS in Endometrial Cancer
Compared with chemotherapy, pembrolizumab monotherapy is associated with improved quality of life and reduces severe treatment-related adverse events.

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

Filter the stories

Sources Ratings and details

Pembrolizumab vs Chemo Improves PFS in Endometrial Cancer

Summary

Who is covering this

Comments